Urine Output during Cardiopulmonary Bypass Predicts Acute Kidney Injury after Coronary Artery Bypass Grafting
AbstractObjective: This study evaluated the relationship between the amount of urinary output during cardiopulmonary bypass and acute kidney injury in the postoperative period of coronary artery bypass grafting.
Methods: Two hundred patients with normal preoperative serum creatinine levels, operated on with isolated CABG between 2012-2014 were investigated retrospectively. The RIFLE (Risk, injury, failure, loss of function, and end-stage renal disease) risk scores were calculated for each patient in the third postoperative day. Patients were distributed into two groups in relation to the presence of acute kidney injury or not and these two groups were compared.
Results: The urinary output (mL/kg/hour) during cardiopulmonary bypass in the acute kidney injury negative group was significantly higher than in the acute kidney injury positive group (P = .022). In case of a urinary output value 3.70 and lower to predict acute kidney injury positivity, sensitivity was detected as 71.43%. Results of the analysis for urinary output predict positivity of acute kidney injury.
Conclusion: We suggest that urine output during cardiopulmonary bypass is a significant criteria that could predict acute kidney injury following coronary artery bypass grafting with cardiopulmonary bypass. Attempts to increase the urine output during cardiopulmonary bypass could help to maintain the renal functions during and after surgery.
Boldt J, Brosch C, Piper SN, Suttner S, Lehmann A, Werling C. 2001. Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients. Crit Care Med 29:952-8.
Boldt J, Brenner T, Lehmann A, Suttner SW, Kumle B, Isgro F. 2003. Is kidney function altered by the duration of cardiopulmonary bypass? Ann Thorac Surg 75:906-12.
Bove T, Calabro MG, Landoni G, et al. 2004. The incidence and risk of acute renal failure after cardiac surgery. J Cardiothorac Vasc Anesth 18:442-7.
Buğra O, Baysal A, Fedakar A, Erdem K, Sunar H, Dağlar B. 2014. Does serum neutrophil gelatinase-associated lipocalin biomarker detect the early deterioration in renal functions in patients with insulin-dependent diabetes mellitus undergoing coronary artery bypass graft surgery? Turk Gogus Kalp Dama 22:63-70.
Cagli K, Ulas MM, Ozisik K, et al. 2005. The intraoperative effect of pentoxifylline on the inflammatory process and leukocytes in cardiac surgery patients undergoing cardiopulmonary bypass. Perfusion 20:45-51.
Cremer J, Martin M, Redl H, et al. 1996. Systemic inflammatory response after cardiac operations. Ann Thorac Surg 61:1714-20.
Cruz DN, Ronco C, Katz N. 2010. Neutrophilgelatinase-associatedlipocalin: a promising biomarker for detecting cardiac surgery associated acute kidney injury. J Thorac Cardiovasc Surg 139:1101-6.
Czerny M, Baumer H, Kilo J, et al. 2000. Inflammatory response and myocardial injury following coronary artery bypass grafting with or without cardiopulmonary bypass. Eur J Cardiothorac Surg 17:737-42.
Fischer UM, Weissenberger WK, Warters RD, Geissler HJ, Allen SJ, Mehlhorn U. 2002. Impact of cardiopulmonary bypass management on postcardiac surgery renal function. Perfussion 17:401-6.
Fransen E, Maessen J, Dentener M, Senden N, Geskes G, Buurman W. 1998. Systemic inflammation present in patients undergoing CABG without extracorporeal circulation. Chest 113:1290-5.
Karkouti K, Beattie WS, Wijeysundera DN, et al. 2005. Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery. J Thorac Cardiovasc Surg 129:391-400.
Kron IL, Yoob AW, Van meter C. 1985. Acute renal failure in the car¬diovascular surgical patient. Ann Thorac Surg 39:590-8.
Kshirsagar AV, Poole C, Mottl A, et al. 2004. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: A meta-analysis of prospective controlled trials. J Am Soc Nephrol 15:761-9.
Loef BG, Henning RH, Epema AH, et al. 2004. Effect of dexamethasone on perioperative renal function impairment during cardiac surgery with cardiopulmonary bypass. Br J Anaesth 93:793-8.
Loef BG, Epema AH, Smilde TD, et al. 2005. Immediate postoperative renal function deterioration in cardiac surgical patients predicts in hospital mortality and long term survival. J Am Soc Nephrol 16:195-200.
Maitra G, Ahmed A, Rudra A, Wankhede R, Sengupta S, Das T. 2009. Renal dysfunction after off-pump coronary artery bypass surgery-risk factors and preventive strategies. Indian J Anaesth 53:401.
Provenchère S, Plantefève G, Hufnagel G, et al. 2003. Renal dysfunction after cardiac surgery with normothermic cardiopulmonary bypass: incidence, risk factors, and effect on clinical outcome. Anesth Analg 96:1258-64.
Regragui IA, Izzat MB, Birdi I, Lapsley M, Bryan AJ, Angelini GD. 1995. Cardiopulmonary bypass perfusion temperaturedoes not influence perioperative renal function. Ann Thorac Surg 60:160-4.
Sucu N, Cinel I, Unlu A, et al. 2004. N-acetylcysteine for preventing pump-induced oxidoinflammatory response during cardiopulmonary bypass. Surg Today 34:237-42.
Thakar CV, Liangos O, Yared JP, Nelson DA, Harihachar S, Paganini EP. 2003. Predicting acute renal failure after cardiac surgery: Validation and redefinition of a risk stratification algo-rithm. Hemodial Int 7:143-7.
Toraman F, Evrenkaya S, Senay S, Karabulut H, Alhan C. 2007. Adjusting oxygen fraction to avoid hyperoxemia during cardiopulmonary bypass. Asian Cardiovasc Thorac Ann 15:303-6.
Tossios P, Bloch W, Huebner A, et al. 2003. N-acetylcysteine prevents reactive oxygen species-mediated myocardial stress in patients undergoing cardiac surgery: Results of a randomized, double-blind, placebo-controlled clinical trial. Thorac Cardiovasc Surg 126: 1513-20.
Urzua J, Troncoso S, Bugedo G, et al. 1992. Renal function and cardiopulmonary bypass: Effect of perfusion pressure. J Cardiovasc Vasc Anesth 6:299-303.
Zhang M, Xu YJ, Saini HK, Turan B, Liu PP, Dhalla NS. 2005. Pentoxifylline attenuates cardiac dysfunction and reduces TNF-alpha level in the ischemic-reperfused heart. Am J Physiol Heart Circ Physiol 289:832-9.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).